Dr. Jean-Baptiste Micol

Dr. Jean-Baptiste Micol is a hemato-oncologist, member of the Gustave Roussy Hematology Committee for chronic myeloid hemopathies (myelodysplastic syndromes) and acute leukemias, and a physician-researcher in the INSERM UMR1287 research unit "Hematopoietic stem cells and the development of myeloid hemopathies".

Dr. Jean-Baptiste Micol graduated from the University of Lille 2 in hematology in 2008. He was first a clinical assistant in the adult hematology department of the Saint-Louis Hospital in Paris between 2008 and 2011. He then joined Gustave Roussy in 2011 as a CLCC specialist. He was also head of the clinical hematology department at Gustave Roussy between 2020 and 2022.

Holder of a Master 2 "Molecular and cellular biology of hematopoiesis" from the University of Paris Diderot in the research unit directed by Dr. Vainchenker, he obtained his doctoral thesis at the Doctoral School of Oncology of the University of Paris Saclay in 2016 while conducting his research in Dr. Abdel-Wahab's team at the Memorial Sloan Kettering Cancer Center in New York (USA) between 2013 and 2016, working on the role of ASXL2 in hematological malignancies.

He was notably awarded the Translational Research Program of the American and European Societies of Hematology (ASH / EHA-TRTH program) in 2015, and the 2016 SFH Prize awarded by the French Society of Hematology.

Today, his research is focused on acute myeloid leukemia, more specifically secondary to treatments for a first cancer, and pre-leukemic states (clonal hematopoiesis).